€1.29
1.49% today
L&S, Jun 28, 12:57 pm CET
ISIN
US69404D1081
Symbol
PACB
Sector
Industry

Pacific Biosciences of California, Inc. Target price 2024 - Analyst rating & recommendation

Pacific Biosciences of California, Inc. Classifications & Recommendation:

Buy
47%
Hold
53%

Pacific Biosciences of California, Inc. Target price

Target price $3.33
Course $1.36
Price potential
Number of estimates 12
12 Analysts have issued a price target Pacific Biosciences of California, Inc. 2025 . The average Pacific Biosciences of California, Inc. target price is $3.33. This is higher than the current share price. The highest price target is , the lowest is .
A rating was issued by 15 analysts: 7 Analysts recommend Pacific Biosciences of California, Inc. to buy, 8 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst estimates: Analysts believe that the Pacific Biosciences of California, Inc. share has an average upside potential 2025 of . Most analysts recommend the Pacific Biosciences of California, Inc. share at Hold.

Sales and margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Forecast
Turnover Million $ 200.52 179.89
56.29% 10.29%
EBITDA margin -138.47% -129.80%
38.20% 6.26%
Net margin -164.30% -139.24%
44.70% 15.25%

14 Analysts have issued a sales forecast Pacific Biosciences of California, Inc. 2024 . The average Pacific Biosciences of California, Inc. sales estimate is

$180m
unlock
. This is
10.25% lower
unlock
than the turnover of the last 12 months(TTM). The highest sales forecast is
$185m 7.71%
unlock
, the lowest is
$167m 16.68%
unlock
.

This results in the following potential growth figures:

Sales forecast

2023 $201m 56.29%
2024
$180m 10.29%
unlock
2025
$235m 30.40%
unlock
2026
$301m 28.38%
unlock
2027
$402m 33.55%
unlock
2028
$390m 3.12%
unlock

9 Analysts have issued an Pacific Biosciences of California, Inc. EBITDA forecast 2024. The average Pacific Biosciences of California, Inc. EBITDA estimate is

$-233m
unlock
. This is
14.35% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-213m 22.02%
unlock
, the lowest is
$-275m 0.88%
unlock
.

This results in the following potential growth figures and future EBITDA margins:

EBITDA forecast

2023 $-278m 3.42%
2024
$-233m 15.91%
unlock
2025
$-174m 25.69%
unlock
2026
$-128m 26.32%
unlock
2027
$-105m 17.83%
unlock
2028
$-118m 12.33%
unlock

EBITDA margin

2023 -138.47% 38.20%
2024
-129.80% 6.26%
unlock
2025
-73.97% 43.01%
unlock
2026
-42.45% 42.61%
unlock
2027
-26.12% 38.47%
unlock
2028
-30.29% 15.96%
unlock

14 Pacific Biosciences of California, Inc. Analysts have issued a net profit forecast 2024. The average Pacific Biosciences of California, Inc. net profit estimate is

$-250m
unlock
. This is
19.30% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-218m 29.83%
unlock
, the lowest is
$-297m 4.38%
unlock
.

This results in the following potential growth figures and future net margins:

Net profit forecast

2023 $-329m 13.57%
2024
$-250m 23.97%
unlock
2025
$-196m 21.85%
unlock
2026
$-149m 24.13%
unlock
2027
$-112m 24.84%
unlock
2028
$-95.3m 14.63%
unlock

Net margin

2023 -164.30% 44.70%
2024
-139.24% 15.25%
unlock
2025
-83.45% 40.07%
unlock
2026
-49.32% 40.90%
unlock
2027
-27.76% 43.71%
unlock
2028
-24.46% 11.89%
unlock

Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Forecast
Earnings per share $ -1.21 -0.92
13.57% 23.97%
P/E ratio negative
EV/Sales 4.11

14 Analysts have issued a Pacific Biosciences of California, Inc. forecast for earnings per share. The average Pacific Biosciences of California, Inc. <a href=/blog/eps>EPS is

$-0.92
unlock
. This is
19.30% higher
unlock
than earnings per share in the financial year 2023. The highest <a href=/blog/eps>EPS forecast is
$-0.80 29.82%
unlock
, the lowest is
$-1.09 4.39%
unlock
.

This results in the following potential growth figures and future valuations:

Earnings per share

2023 $-1.21 13.57%
2024
$-0.92 23.97%
unlock
2025
$-0.72 21.74%
unlock
2026
$-0.55 23.61%
unlock
2027
$-0.41 25.45%
unlock
2028
$-0.35 14.63%
unlock

P/E ratio

Current -1.19 87.69%
2024
-1.48 24.37%
unlock
2025
-1.89 27.70%
unlock
2026
-2.49 31.75%
unlock
2027
-3.32 33.33%
unlock
2028
-3.89 17.17%
unlock

Based on analysts' sales estimates for 2024, the Pacific Biosciences of California, Inc. share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of

and an <a href=/blog/kurs-umsatz-verhaeltnis-kuv-einfach-erklaert>P/S ratio of .

This results in the following potential growth figures and future valuations:

EV/Sales

Current 3.69 84.52%
2024
4.11 11.41%
unlock
2025
3.15 23.31%
unlock
2026
2.46 22.10%
unlock
2027
1.84 25.12%
unlock
2028
1.90 3.22%
unlock

P/S ratio

Current 1.85 92.07%
2024
2.06 11.42%
unlock
2025
1.58 23.31%
unlock
2026
1.23 22.11%
unlock
2027
0.92 25.11%
unlock
2028
0.95 3.21%
unlock

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now